© 2004 by Oxford University Press
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2004 Oxford University Press
ARTICLE |
A Prospective Study of Plasma Selenium Levels and Prostate Cancer Risk
Affiliations of authors: Channing Laboratory, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA (HL, MJS, ELG, WCW, JM); Departments of Epidemiology and Nutrition, Harvard School of Public Health, Boston (MJS, ELG, WCW); Research Reactor Center, University of Missouri-Columbia, Columbia (JSM); Division of Preventive Medicine, Brigham and Women's Hospital and Harvard Medical School, and Massachusetts Veterans Epidemiology Research and Information Center (MAVERIC), VA Boston Healthcare System, Boston (JMG).
Correspondence to: Haojie Li, MD, PhD, Channing Laboratory, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Rm. 452, 181 Longwood Ave., Boston, MA 02115 (e-mail: haojie.li{at}channing.harvard.edu)
Background: Epidemiologic studies suggest that low selenium levels are associated with an increased incidence of prostate cancer, although results are conflicting. We examined the association between pre-diagnostic plasma selenium levels and risk of prostate cancer in men enrolled in the Physicians' Health Study. Methods: Using plasma samples obtained in 1982 from healthy men enrolled in the study, we conducted a nested case–control study among 586 men diagnosed with prostate cancer during 13 years of follow-up and 577 control subjects. Odds ratios (ORs) and 95% confidence intervals (CIs) for the risk of prostate cancer in pre- (before October 1990) and post- (after October 1990) prostate-specific antigen (PSA) screening eras were calculated using multivariable logistic regression. Results: Pre-diagnostic plasma selenium levels were inversely associated with risk of advanced prostate cancer (5th versus 1st quintile OR = 0.52, 95% CI = 0.28 to 0.98; Ptrend = .05), even among men diagnosed after 1990 (5th versus 1st quintile OR = 0.39, 95% CI = 0.16 to 0.97). The inverse association with prostate cancer risk was observed only for case subjects with elevated baseline PSA levels (PSA >4 ng/mL, 5th versus 1st quintile OR = 0.49, 95% CI = 0.28 to 0.86; Ptrend = .002). These inverse associations were observed in both pre- and post-PSA eras. Conclusions: The inverse association between baseline plasma selenium levels and risk of advanced prostate cancer, even among men diagnosed during the post-PSA era, suggests that higher levels of selenium may slow prostate cancer tumor progression. Ongoing randomized trials of selenium supplements may help to further evaluate this issue.
CiteULike 
Connotea 
Del.icio.us What's this?
Editorial about this Article
- Science Peels the Onion of Selenium Effects on Prostate Carcinogenesis
- Philip R. Taylor, Howard L. Parnes, and Scott M. Lippman
J Natl Cancer Inst 2004 96: 645-647.[Extract] [Full Text] [PDF]
This article has been cited by other articles:
|
|
 |
|
  D. J. Waters, S. Shen, H. Xu, S. S. Kengeri, D. M. Cooley, E. C. Chiang, Y. Chen, D. Schlittler, C. Oteham, G. F. Combs Jr., et al. Noninvasive Prediction of Prostatic DNA Damage by Oxidative Stress Challenge of Peripheral Blood Lymphocytes Cancer Epidemiol. Biomarkers Prev., September 1, 2007; 16(9): 1906 - 1910. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Y. Chun, Y. Hu, E. Pinder, J. Wu, F. Li, and A. C. Gao Selenium inhibition of survivin expression by preventing Sp1 binding to its promoter Mol. Cancer Ther., September 1, 2007; 6(9): 2572 - 2580. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Nagata, T. Sonoda, M. Mori, N. Miyanaga, K. Okumura, K. Goto, S. Naito, K. Fujimoto, Y. Hirao, A. Takahashi, et al. Dietary Isoflavones May Protect against Prostate Cancer in Japanese Men J. Nutr., August 1, 2007; 137(8): 1974 - 1979. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. H. Kim, S. Sohn, H. J. Kwon, S. U. Kim, M.-J. Kim, S.-J. Lee, and K. S. Choi Sodium Selenite Induces Superoxide-Mediated Mitochondrial Damage and Subsequent Autophagic Cell Death in Malignant Glioma Cells Cancer Res., July 1, 2007; 67(13): 6314 - 6324. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. Peters, C. B Foster, N. Chatterjee, A. Schatzkin, D. Reding, G. L Andriole, E D. Crawford, S. Sturup, S. J Chanock, and R. B Hayes Serum selenium and risk of prostate cancer--a nested case-control study Am. J. Clinical Nutrition, January 1, 2007; 85(1): 209 - 217. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Fairfield and M. Stampfer Vitamin and mineral supplements for cancer prevention: issues and evidence Am. J. Clinical Nutrition, January 1, 2007; 85(1): 289S - 292S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Diwadkar-Navsariwala, G. S. Prins, S. M. Swanson, L. A. Birch, V. H. Ray, S. Hedayat, D. L. Lantvit, and A. M. Diamond Selenoprotein deficiency accelerates prostate carcinogenesis in a transgenic model PNAS, May 23, 2006; 103(21): 8179 - 8184. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Y. Chun, N. Nadiminty, S. O. Lee, S. A. Onate, W. Lou, and A. C. Gao Mechanisms of selenium down-regulation of androgen receptor signaling in prostate cancer. Mol. Cancer Ther., April 1, 2006; 5(4): 913 - 918. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. L. Sabichi, J. J. Lee, R. J. Taylor, I. M. Thompson, B. J. Miles, C. M. Tangen, L. M. Minasian, L. L. Pisters, J. R. Caton, J. W. Basler, et al. Selenium accumulation in prostate tissue during a randomized, controlled short-term trial of l-selenomethionine: a Southwest Oncology Group Study. Clin. Cancer Res., April 1, 2006; 12(7 Pt 1): 2178 - 2184. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Zhao, N. Xiang, F. E. Domann, and W. Zhong Expression of p53 Enhances Selenite-Induced Superoxide Production and Apoptosis in Human Prostate Cancer Cells Cancer Res., February 15, 2006; 66(4): 2296 - 2304. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Kohrle, F. Jakob, B. Contempre, and J. E. Dumont Selenium, the Thyroid, and the Endocrine System Endocr. Rev., December 1, 2005; 26(7): 944 - 984. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Chan, P. H. Gann, and E. L. Giovannucci Role of Diet in Prostate Cancer Development and Progression J. Clin. Oncol., November 10, 2005; 23(32): 8152 - 8160. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Li, P. W. Kantoff, E. Giovannucci, M. F. Leitzmann, J. M. Gaziano, M. J. Stampfer, and J. Ma Manganese Superoxide Dismutase Polymorphism, Prediagnostic Antioxidant Status, and Risk of Clinical Significant Prostate Cancer Cancer Res., March 15, 2005; 65(6): 2498 - 2504. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Lippman, P. J. Goodman, E. A. Klein, H. L. Parnes, I. M. Thompson, A. R. Kristal, R. M. Santella, J. L. Probstfield, C. M. Moinpour, D. Albanes, et al. Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT) J Natl Cancer Inst, January 19, 2005; 97(2): 94 - 102. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. R. Taylor and P. Greenwald Nutritional Interventions in Cancer Prevention J. Clin. Oncol., January 10, 2005; 23(2): 333 - 345. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Borek Dietary Antioxidants and Human Cancer Integr Cancer Ther, December 1, 2004; 3(4): 333 - 341. [Abstract] [PDF]
|
|
|
|
|
|
M. F. McCarty Targeting Multiple Signaling Pathways as a Strategy for Managing Prostate Cancer: Multifocal Signal Modulation Therapy Integr Cancer Ther, December 1, 2004; 3(4): 349 - 380. [Abstract] [PDF]
|
|
|
|
|
|
P. R. Taylor, H. L. Parnes, and S. M. Lippman Science Peels the Onion of Selenium Effects on Prostate Carcinogenesis J Natl Cancer Inst, May 5, 2004; 96(9): 645 - 647. [Full Text] [PDF]
|
|